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Non-memory cognitive symptom 
development in Alzheimer's disease 
Abstract 
BACKGROUND: Memory is known to be the most common first symptom in Alzheimer’s Disease. 
Assessing non-memory cognitive symptom development in Alzheimer’s Disease is important for 
understanding disease progression and the potential identification of treatment-responsive 
subtypes.  
METHODS: Data from the National Alzheimer Co-ordinating Center were examined. Logistic 
regression models were fitted evaluating development of judgement, language, visuospatial and 
attention symptoms at first and second visits to Alzheimer’s Disease Centers. Predictors were age 
and prior symptoms, adjusting for symptom length and sex. The models were then refitted assessing 
APOE-ε4 effects. 
RESULTS: Each decade reduction in presentation age increased the odds of language, visuospatial 
and attention symptom development at both visits by 8-18% (p<0.05, all tests), and judgement 
symptoms at second visit by 13% (p<0.05). Prior symptoms were not equally predictive of symptom 
development. For example, having first-predominant language symptoms carried the lowest risk of 
developing other first-visit symptoms and having memory symptoms was a stronger predictor of 
developing judgement than other symptoms. The APOE-ε4 gene showed little impact on symptom 
development when included as a predictor.  
CONCLUSIONS: Our findings provide support for the concept that younger-onset AD is associated 
with the progressive development of more non-memory symptoms beyond the first time point. 
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Associations between symptoms were evident, which may reflect that pathology can remain isolated 
in a network for some time. APOE-ε4 status had little influence on cognitive symptom development 
which may indicate that the effect it has occurs very early in the disease course. 
1. Introduction 
It is increasingly recognised that memory dysfunction is not always the first or the only cognitive 
symptom experienced by those with Alzheimer’s disease (AD) [1–7]. Many patients experience non-
memory cognitive symptoms as their first symptom and those with younger onset (usually onset 
before 65 years) are more likely to have early non-memory symptoms than older patients [3–7]. 
There is increased recognition of non-amnestic subtypes of AD including language, visuospatial 
presentations and executive dysfunction [2]. Less understood is whether there is a pattern of non-
memory cognitive symptom development and whether patient variables are important predictors. It 
has been suggested that the biggest genetic risk factor for sporadic AD (the APOE-ε4 allele [8]) may 
influence the presentation [9,10]. For example, those with an ε4 allele are more likely to have 
memory as the first predominant symptom or an isolated amnestic presentation [11].  
The presence of cognitive symptoms, as opposed to neuropsychological test scores, is important to 
investigate as symptoms are easy to evaluate and closely relate to patients’ experiences. Further, 
non-memory symptom data associate with activities of daily living suggesting that patients’ lives are  
affected when symptoms are present [12,13].  However, symptom data can be difficult to analyse 
due to their categorical nature. A high prevalence of specific symptoms can also be problematic if 
comparisons are made between individuals with and without a symptom, or in analyses assessing 
predictors of developing a symptom, so large datasets are required. 
In this study we used an AD patient dataset to examine the relationship between age and the 
development of new non-memory cognitive symptoms, and whether previously-recorded symptoms 
influenced non-memory symptom development. Finally, the influence of APOE-ε4 was examined. 
We hypothesised that: younger AD patients would be more likely to develop non-memory cognitive 
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symptoms; there was likely to be an influence of prior symptoms on symptom development; those 
without an APOE-ε4 gene were more likely to develop non-memory symptoms.  
2. Methods 
2.1 Subjects 
AD patient data collected by the National Alzheimer’s Coordinating Center (NACC) were analysed. 
NACC maintains a database of standardized clinical research data from individuals with normal 
cognition, mild cognitive impairment and neurodegenerative diseases, collected from past and 
present NIA-funded US Alzheimer’s Disease Centers (ADCs). Written informed consents were 
obtained from participants and the study was approved by an Institutional Review Board (IRB) at 
each ADC. Research using the NACC database was approved by the University of Washington IRB. 
NACC recruitment and data collection has been described previously [14]. Data included patients 
seen at 34 ADCs between study inception in 2005 and May 2016. Our study required subjects 
diagnosed with probable or possible AD according to standard diagnostic criteria [15] at their first 
NACC visit (n>9000).  
  
Since most patients only had early visit data, analyses were restricted to the first two NACC visits. At 
each visit, patients were assessed by their clinician for the presence or absence of up to seven 
cognitive symptoms and “other” cognitive symptoms. The clinician’s judgement was used to 
determine symptom presence in consultation with the patient and caregivers. Missing data were 
typically due to information not being collected or changes in versions of datasheets. The first 
predominant cognitive symptom was recorded by the clinician, indicating which of the symptom 
categories was first recognized as a decline in the subject’s cognition. The age at which the clinician 




Descriptive summaries of each first predominant cognitive symptom were used to identify 
symptoms as outcome variables in the analysis.  Memory was excluded since its high frequency 
meant that few patients were at risk of developing this symptom during follow-up.  Cognitive 
symptoms reported in only small numbers of patients were excluded as outcome variables since 
their rarity would make the statistical power of analyses low. 
 
2.2 Variables  
We used first predominant cognitive symptoms reported at first visit, first and second visit cognitive 
symptoms, symptom duration (between age of decline and age of presentation), interval between 
the first and second visits, age of presentation, and gender. Mini-mental state examination scores at 
first visit were also used for group characterisation.  
2.3 Statistical analysis 
All analyses were conducted in Stata v15. Summary statistics were produced for the variables of 
interest. Missing responses for symptom presence were explored for both visits. 
Logistic regression was the primary method of analysis. The outcome in each model was the 
development of a symptom never previously reported. Different models were used for symptom 
development at the first and second NACC visits since only first predominant symptom was available 
for predicting symptoms at first visit, whereas presence of each of the other symptoms at first visit 
was also available at the second visit.  
Each first visit symptom outcome was modelled separately; modelling the odds of developing the 
cognitive symptoms of interest at the first NACC visit, conditional on this not being the first 
predominant cognitive symptom. Therefore, we only explore new symptoms developed between 
the first predominant symptom and first visit. The predictors of interest were age at first visit, and 
the first predominant cognitive symptom, adjusting for gender and symptom duration.  
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The odds of developing symptoms at the second visit were modelled, conditional on the symptom 
neither being the first predominant cognitive symptom nor reported at visit 1. Predictors of interest 
were age at first visit, first predominant cognitive symptom, first visit cognitive symptoms, with 
adjustment for gender, symptom duration prior to first visit and the inter-visit interval. Joint Wald 
tests assessed whether there was evidence that the first predominant cognitive symptom remained 
a predictor at visit 2, after adjusting for visit 1 symptoms. Models were fitted omitting the first 
predominant symptom if found not to improve model fit. Joint Wald tests assessed whether there 
was evidence that the odds ratios associated with each first visit cognitive symptom predictor were 
heterogeneous.  
To explore APOE-ε4 effects, each of the models described above was re-fitted, adjusting for 
categorical ε4 allele number. 
3. Results 
3.1 Demographics 
9484 patients attended the first NACC visit, with 87% reporting memory impairment as the first 
predominant cognitive symptom (see table 1 for summary statistics). Proportions of patients with 
each reported cognitive symptom at each visit are shown in figure 1. Four non-memory symptoms 
(impairments of judgement, language, visuospatial function and attention) were deemed sufficiently 
prevalent to include as outcomes in the symptom development models. See supplementary table S1 




Mean age at first visit (SD) [Range] 74.9 (9.9) [35-110] 
Mean MMSE at first visit (SD) [Range] 19.3 (6.8) [0-30] 
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Women (%) 5283 (56) 
Symptom duration in years (SD) 4.8 (3.4) 
Time between visits 1 and 2, years (SD) 1.2 (0.4) 
Attended visit 1 (%) 9484 (100) 
Attended visit 2 (%) 5538 (58) 
APOE-ε4 alleles (%)*           0 2913 (30.7)    
                                                1 3046 (32.1) 




Memory 8257 (87) 
Orientation 0 (0) 
Judgement 413 (4) 
Language 429 (5) 
Visuospatial function 230 (2) 
Attention/concentration 82 (0.8) 
Fluctuating cognition 4 (<0.1) 
Other 38 (0.4) 
Unknown 31 (0.3) 
Table 1: Patient characteristics for the whole AD group  
* Data missing for 2640 (27.8%) patients 





Figure 1: AD patients reporting each cognitive symptom at visits 1 (n=9484) and 2 (n=5538) 
58% of patients attended both visits; orientation and “other” were the most frequently missing 
symptoms, with patients only asked about orientation symptoms at visit 2, so this was missing at 
visit 1.  
3.2 First visit 
Results from models relating development of first visit symptoms to age at presentation, symptom 
duration, gender and first predominant cognitive symptom are shown in figure 2. There was 
evidence that older patients were less likely to develop language, visuospatial and attention 
symptoms, with a decade later age of presentation associated with an estimated 8 to 18% decrease 
in the odds of reporting these. An increase in symptom duration prior to first visit increased the 
likelihood of developing all non-memory symptoms, with a one-year increase in length of symptoms 
associated with estimated increases in odds of reporting these symptoms of 12 to 21%. Gender 
effects differed according to symptom: women were more likely to develop impaired judgement 
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(19% increase in odds) and attention (11% increase in odds) symptoms while men were more likely 
to develop language symptoms (11% increase in odds).   
Amongst the common first predominant symptoms, memory carried the highest risk for 
development of impaired judgement. Language and visuospatial function carried the lowest; the 
odds were lower and statistically significant for both compared with memory. Having language 
impairment as the first predominant symptom also carried the lowest risk of developing visuospatial 
symptoms (statistically significantly lower than memory) and the lowest risk of developing attention 
symptoms, although here differences between first predominant symptoms were less marked, with 
only judgement carrying a higher risk than the other common first predominant symptoms. For 
development of language symptoms, having memory or visuospatial function as the first 
predominant symptom carried the lowest risks, with the risk for memory being statistically 




Figure 2: Comparative odds ratios (95% CI) for the development of each of four cognitive symptoms at visit 1 
(n/N=number of patients who developed symptom/number at risk). Some 95% CI extend beyond the shown 
range. 
3.3 Second visit 
The estimated associations between development of second visit symptoms and age at 
presentation, symptom length, time between visits, gender and first visit symptoms are shown in 
figure 3. Wald tests indicated that after adjusting for the symptoms reported at visit 1, there was no 
evidence of a residual predictive effect of first predominant cognitive symptom (p>0.1, all tests, see 
supplementary table S2).  
There was strong evidence that younger subjects were more likely to develop all non-memory 
cognitive symptoms, with increases in the odds of reporting these symptoms at visit 2 varying from 
11 to 23% for a decade later presentation age. Women had 34% lower odds than men of developing 
judgement symptoms at visit 2. Time between visits was strongly positively predictive of the 
development of all non-memory cognitive symptoms.  
Where there was evidence that first visit symptoms were predictive of second visit symptoms, the 
relationship was positive. The Wald tests suggested that visit 1 symptoms were not equally 
predictive of development of judgement and visuospatial function symptoms. Memory problems at 
visit 1 more than tripled the odds of developing judgement symptoms at visit 2. For visuospatial 
symptoms at visit 2, memory and judgement symptoms were the strongest predictors, each 
approximately doubling the odds of development. For development of visit 2 language and attention 
symptoms, there was no evidence that symptoms were unequally predictive.  
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Figure 3: Comparative odds ratios (95% CI) for the development of each of four cognitive symptoms at visit 2 
(n/N=number of patients who developed symptom/number at risk). Some 95% CI extend beyond the shown 
range. 
3.4 The effect of APOE-ε4  
The effect of APOE-ε4 was typically small, with no consistent pattern in the direction of estimated 
effects (see supplementary table S3). There was one statistically significant result; notably with 
sixteen analyses the danger of a false-positive is high.  
4. Discussion 
Our study found that each decade reduction in presentation age was associated with development 
of non-memory cognitive symptoms over time, and first visit symptom development differed 
according to first predominant cognitive symptom. Memory carried the highest risk and language 
the lowest of developing impaired judgement. Having language as the first predominant symptom 
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also carried the lowest risk of developing visuospatial and attention symptoms. For development of 
language symptoms, memory or visuospatial functioning as first predominant cognitive symptom 
carried the lowest risks. Considering non-memory cognitive symptoms at visit 2, only symptoms 
developed by visit 1 were predictive of symptom development. Having memory symptoms was a 
markedly stronger predictor than the others for developing judgement symptoms. Gender had some 
influence over first visit symptom development (women were more likely to develop attention and 
judgement symptoms, but less likely to develop language symptoms). At the second visit, men were 
more likely to develop judgement symptoms. There was no convincing evidence that APOE-ε4 was 
predictive of non-memory cognitive symptoms.  
Finding that younger patients were more likely to develop three of the four non-memory cognitive 
symptoms between the first predominant symptom occurring and first visit is consistent with the 
view that younger patients are more likely to have a more non-memory presentation. Further, these 
results show that more non-memory cognitive domains are affected faster in younger patients. The 
evidence for patterns of prediction of symptom development may support the theory that pathology 
can be isolated within specific brain networks before spreading. 
The effects of age on presentation observed are consistent with other studies indicating that 
younger patients have more non-memory cognitive symptoms [3–7]. One similar study assessing 
development of cognitive problems demonstrated that younger patients were more likely to 
develop language and concentration problems over time [16].  
Finding that language impairment carried the lowest risk for developing other non-memory cognitive 
symptoms at first visit is possibly attributable to isolated and focal damage at early disease stages 
[17].  
We found some influence of gender on symptom development, particularly at first visit. Results in 
the literature are mixed. Two studies have shown no significant differences in gender between 
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typical and atypical AD groups [5,18]. Other studies have shown differences: one showed the visual 
variant of AD were slightly more likely to be female [11]; another that women were more likely to 
have first predominant memory symptoms than non-memory symptoms [3].  
Our lack of significant predictive results for APOE-ε4 seems at odds with the literature [3,11,19]. 
However, results are mixed: recent work has shown the ε4 allele to be associated with increased risk 
of posterior cortical atrophy (PCA) [20]. Other work has shown that visuospatial, executive 
functioning and attention problems differ in early vs. late AD and this age effect is unchanged by 
adjusting for APOE-ε4 [21]. Our current work differs from previous analyses as it assesses non-
memory cognitive symptom development, including those with memory as a first symptom, 
adjusting for whether an individual had the symptom previously. Therefore, many non-carriers will 
have memory as the first symptom. Our data may thus imply that the APOE-ε4 effect on 
presentation occurs early in the disease and little effect remains once prior symptoms are accounted 
for.   
The main strength of our study is that it is a large multi-site study with systematic data collection. 
However, we did not examine autopsy-confirmed AD cases; our findings may be influenced by 
misdiagnoses which may be more prevalent in younger-onset cases [5]. Missing data was present in 
our analyses due to rolling recruitment and subject withdrawal and not all subjects had APOE 
testing. Collection of first predominant symptom and age of decline carries risks of recall bias; more 
objective measures of cognitive function, such as neuropsychological test results, were not 
investigated. The NACC dataset represents a convenience dataset; the patients are not necessarily 
representative of the wider AD population. We cannot make conclusions regarding the weight of 
specific symptoms beyond the first predominant symptom. The initial symptom may still 
predominate patients’ experiences throughout the disease [11]. 
Younger-onset patients develop more non-memory symptoms, allowing for already-acquired 
symptoms, suggesting a different course of AD in these patients. APOE-ε4 genotype does not explain 
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these findings, suggesting that other genes may have a role in non-memory symptom development. 
Non-memory cognitive symptoms are important to assess, especially in younger-onset cases. 
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